Please assess the completion status of the following clinical trial:

Trial Title: Enzastaurin in Combination of Capecitabine to Treat Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed with metastatic or recurrent breast cancer.~* Have been previously treated with both an anthracycline and a taxane.~* Have not received more than two prior chemotherapy treatment programs.~* Have stopped any antitumoral hormonal treatment before you enroll in this study.~* Have a negative pregnancy blood test if menstruating or capable of becoming pregnant. You must use an approved birth control method during the study and for 3 months after stopping study treatment.~Exclusion Criteria:~* Cannot follow the study procedures (for example, you cannot swallow tablets).~* Are receiving another treatment for your cancer.~* Have received another experimental drug in the last 4 weeks.~* Have had serious heart disease within last 6 months.~* Are pregnant or breast-feeding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Capecitabine + Enzastaurin (Type: EXPERIMENTAL): None
- Capecitabine + Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).